India's Cheap Weight-Loss Drugs Could Reshape Global Obesity Fight

With India's semaglutide patent expiring on March 20, approximately 50 branded generics are expected to enter the market, drastically lowering costs for weight-loss medication. This influx of affordable alternatives could reshape the global fight against obesity by making treatments accessible to a much broader demographic. The shift challenges current pricing models in the pharmaceutical industry and may force Western markets to reconsider their reliance on expensive branded drugs.